Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. The company was founded in 1979 and is based in Marlborough, Massachusetts.
BSX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Boston Scientific Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Boston Scientific Corp ranked in the 15th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for BSX, they are:
Boston Scientific Corp's effective tax rate, as measured by taxes paid relative to net income, is at 121 -- greater than 97.6% of US stocks with positive free cash flow.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than 60.79% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Boston Scientific Corp? See TECH, A, EW, QGEN, and TFX.
Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures. Available on the RHYTHMIA HDx™ Mapping System, the DIRECTSENSE Technology, which received U.S. Food and Drug Administration approval in April, is the only tool to monitor changes in local impedance – electrical resistance – around the tip of the INTELLANAV™ MiFi Open-Irrigated (OI) ablation catheter, offering physicians an additional measurement of therapy effect during an ablation.
Hello, New York. Atlanta. Los Angeles. Denver. Dallas. Detroit. Washington, DC. Seattle. Miami. Chicago. Thousands marched in cities across the US last night, with many of the protests turning violent. The protests first broke out in Minneapolis after a black man, George Floyd, was killed after a white police officer knelt on his neck for nearly nine minutes during an arrest, and as Floyd said he couldn't breathe. The arrest was caught on video, and the Minneapolis police officer who knelt on George Floyd's neck has since been charged with third-degree murder and manslaughter . As Tati Bellamy Walker and Shana Lebowitz report, a memo from medical-device-manufacturing firm Boston Scientific on the killing of George Floyd is a case study in how leaders should address the events in Minneso...
MARLBOROUGH, Mass. , May 27, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 3,832,500 additional shares of common stock, at a public offering price of $34.25 per share and (ii) 10,062,500 shares of its 5.50% Mandatory Convertible Preferred Stock, Series A ("Mandatory Convertible Preferred Stock"), which includes the exercise in full by the underwriters of their overallotment option to purchase up to 1,312,500 additional shares of Mandatory Convertible Preferred Stock, at a price to the public and liquidation preference of $100.00 per share (collectively, the "offerings"). The net proceeds from the Comm...